Why the study?
Does propofol-remifentanil TIVA compared to isoflurane anesthesia reduce in-hospital MAEs and one-year MACCEs in patients undergoing off-pump coronary arterial bypass surgery?
Does propofol-remifentanil TIVA compared to isoflurane anesthesia reduce in-hospital MAEs and one-year MACCEs in patients undergoing off-pump coronary arterial bypass surgery?
The choice between propofol-remifentanil TIVA and isoflurane anesthesia does not significantly affect in-hospital MAEs or one-year MACCEs after OPCAB, though TIVA may increase the risk of postoperative arrhythmias.
Should not yet change anesthesia choice in OPCAB; leaves open whether TIVA affects MAEs or MACCEs versus isoflurane.
Despite numerous previous studies, there is little data on the effects of anesthetics on clinical outcome after off-pump coronary arterial bypass grafting (OPCAB). Therefore, we retrospectively compared the effects of anesthetic choice on in-hospital major adverse events (MAEs) and one-year major adverse cardiovascular and cerebral events (MACCEs) in patients undergoing OPCAB. Electronic medical records were reviewed in 192 patients who received propofol-remifenanil total intravenous anesthesia (TIVA) and propensity score-matched 662 patients who received isoflurane anesthesia. The primary endpoints were in-hospital MAEs and one-year MACCEs. The components of in-hospital MAEs were in-hospital death, myocardial infarction (MI), coronary revascularization, stroke, renal failure, prolonged mechanical ventilation longer than 72 h, and postoperative new cardiac arrhythmia requiring treatment. One-year MACCEs was defined as a composite of all-cause mortality, MI, coronary revascularization, and stroke. There was no significant difference in risk of in-hospital MAEs (OR = 1.29, 95% CI = 0.88-1.88, P = 0.20) or one-year MACCEs (OR = 0.81; 95% CI = 0.46-1.42, P = 0.46) between the groups. The risk of postoperative new arrhythmia including new atrial fibrillation significantly increased in the TIVA group compared to the isoflurane anesthesia group (OR = 1.72, 95% CI = 1.12-2.63, P = 0.01). In conclusion, the choice between propofol-remifentanil TIVA and isoflurane anesthesia did not show differences in incidence of in-hospital MAEs or one-year MACCEs in patients undergoing OPCAB. However, further studies on the effects of anesthetics on development of in-hospital new arrhythmia will be needed.
No takes yet. Share an insight, caveat, or question.
Min et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: